In a report released today, Judah Frommer from Morgan Stanley maintained a Sell rating on Galapagos (GLPG – Research Report), with a price ...

Shares of Galapagos NV GLPG, a clinical-stage company, are rising in the premarket hours on Aug 23, after the FDA cleared its ...

In this article, we are going to take a look at where Galapagos NV (NASDAQ:GLPG) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile in the market due ...

Shares of Galapagos (NASDAQ:GLPG) (OTCPK:GLPGF) ended a four-day winning streak on Friday after Morgan Stanley downgraded the Belgian biotech, citing its decision to deprioritize its CAR-T therapy ...

GLPG has been the subject of a number of research reports. Royal Bank of Canada reduced their price target on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating for ...

Galapagos NV (GLPG) has been beaten down lately with too much selling pressure. While the stock has lost 21.2% over the past four weeks, there is light at the end of the tunnel as it is now in ...

In trading on Tuesday, shares of Galapagos NV (Symbol: GLPG) crossed above their 200 day moving average of $27.07, changing hands as high as $27.48 per share. Galapagos NV shares are currently ...

Galapagos NV (AMS:GLPG) shareholders should be happy to see the share price up 13% in the last week. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Five years have ...

Shares of Galapagos NV (NASDAQ:GLPG – Get Free Report) have earned an average rating of “Strong Sell” from the nine analysts that are covering the firm, Marketbeat reports. Five investment analysts ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...